Home › Cancro al seno triplo negativo › North Carolina › Durham
Studi clinici su Cancro al seno triplo negativo a Durham, NC
12 studi su Cancro al seno triplo negativo cercano partecipanti presso sedi a Durham e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
In reclutamentoFase 1/2
- Duke University, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
In reclutamentoFase 2
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · a 10 mi di distanza
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
In reclutamentoFase 3
- Duke Cancer Institute, Durham
- Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
In reclutamentoFase 2
- Duke University, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
In reclutamentoFase 2/3
- Duke Cancer Institute, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
In reclutamentoFase 2
- Duke University Medical Center, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
In reclutamentoFase 1
- University of North Carolina, Chapel Hill · a 10 mi di distanza
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
In reclutamentoFase 1
- Duke Cancer Institute /ID# 276267, Durham
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
In reclutamentoFase 2
- The University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi di distanza
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
In reclutamentoFase 2
- University of North Carolina, Chapel Hill · a 10 mi di distanza
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
In reclutamentoFase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
A Study of NX-1607 in Adults With Advanced Malignancies
In reclutamentoFase 1
- University of North Carolina, Chapel Hill · a 10 mi di distanza
Studi su Cancro al seno triplo negativo in altre città
- Houston, TX42 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Los Angeles, CA27 studi
- Boston, MA26 studi
- San Antonio, TX23 studi
- St. Louis, MO21 studi
- Arlington, VA20 studi
- Atlanta, GA20 studi
- Dallas, TX18 studi
- Chicago, IL16 studi
- Columbus, OH16 studi
Altri studi a Durham
- Cancro al seno64 studi
- Cancro (tutti i tipi)58 studi
- Cancro del polmone non a piccole cellule39 studi
- Mieloma multiplo37 studi
- Leucemia mieloide acuta33 studi
- Cancro metastatico33 studi
- Cancro alla prostata32 studi
- Cancro ai polmoni32 studi
- Cancro colorettale28 studi
- Cancro ovarico27 studi
- Leucemia linfatica cronica27 studi
- Insufficienza cardiaca26 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.